Magnetic Resonance of Small Bowel Tumors

Masselli, Gabriele; Guida, Marianna; Laghi, Francesca; Polettini, E; Gualdi, Gianfranco

doi:10.1016/j.mric.2019.08.005

Cited by 20 publications

(28 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies using contrast‐enhanced computed tomography have documented various enhancement patterns of human intestinal lymphoma, with 1 study reporting inhomogeneous hyperintensity . In addition, mild to moderate enhancement is a common feature of contrast‐enhanced magnetic resonance imaging of intestinal lymphoma . These reports suggest hypervascularization of intestinal lymphoma in human; but, this finding was not observed consistently in all cases.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of duodenal perfusion by contrast‐enhanced ultrasonography in dogs with chronic inflammatory enteropathy and intestinal lymphoma

Nisa

Lim

Shinohara

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Contrast‐enhanced ultrasonography (CEUS) can be used to evaluate intestinal perfusion in healthy dogs. It is helpful for diagnosing and monitoring inflammatory bowel disease in humans and could be useful for dogs with chronic intestinal diseases. Objectives To examine duodenal perfusion in dogs with chronic inflammatory enteropathy (CIE) and intestinal lymphoma. Animals Client‐owned dogs with CIE (n = 26) or intestinal lymphoma (n = 7) and dogs with gastrointestinal signs but histopathologically normal duodenum (controls, n = 14). Methods In this cross‐sectional study, dogs with CIE were classified into remission (n = 16) and symptomatic (n = 10) groups based on clinical scores determined at the time of CEUS. The duodenum was scanned after IV injection of Sonazoid® (0.01 mL/kg). CEUS‐derived perfusion parameters, including time‐to‐peak, peak intensity (PI), area under the curve (AUC), and wash‐in and wash‐out rates were evaluated. Results The PI was significantly higher in the symptomatic CIE group (median (range); 105.4 (89.3‐128.8) MPV) than in the control group (89.9 (68.5‐112.2) MPV). The AUC was significantly higher in the symptomatic CIE group (4847.9 (3824.3‐8462.8) MPV.sec) than in the control (3448.9 (1559.5‐4736.9) MPV.sec) and remission CIE (3862.3 (2094.5‐6899.0) MPV.sec) groups. The PI and clinical score were positively correlated in the CIE group. No significant differences in perfusion parameters were detected between the lymphoma and CIE groups or the lymphoma and control groups. Conclusions and Clinical Importance The PI and AUC can detect duodenal inflammation and hence are potentially useful for excluding a diagnosis of CIE.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of duodenal perfusion by contrast‐enhanced ultrasonography in dogs with chronic inflammatory enteropathy and intestinal lymphoma

Nisa

Lim

Shinohara

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Cross-sectional imaging studies including CT and MRI allow identification and characterization of mural or extraluminal lesions, as well as larger intraluminal lesions. CT and MRI are also superior in assessing the extraluminal extent of disease (28).…”

Section: Introductionmentioning

confidence: 99%

Small Bowel Neoplasms: A Pictorial Review

Carucci

2020

RadioGraphics

View full text Add to dashboard Cite

show abstract

“…Conventional imaging with computed tomography (CT) or magnetic resonance (MR) should be used for staging purpose. However, newer imaging techniques, such as CT or MR enterography or enteroclysis, can be taken into consideration after the failure of conventional imaging, if clinical suspicion persists [ 26 , 27 ].…”

Section: Clinical Presentation and Initial Diagnostic Workupmentioning

confidence: 99%

Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management

et al. 2022

View full text Add to dashboard Cite

Small bowel adenocarcinoma (SBA) is a rare malignancy, with a rising incidence in recent decades, and accounts for roughly 40% of all cancers of the small bowel. The majority of SBAs arise in the duodenum and are associated with a dismal prognosis. Surgery remains the mainstay of treatment for localized disease, while systemic treatments parallel those used in colorectal cancer (CRC), both in the adjuvant and palliative setting. In fact, owing to the lack of prospective data supporting its optimal management, SBA has historically been treated in the same way as CRC. However, recent genetic and molecular data suggest a distinct profile from other gastrointestinal malignancies and support a more nuanced approach to its management. Herein, we briefly review the state-of-the-art in the clinical management of early-stage and advanced disease and recent discoveries of potentially actionable genetic alterations or pathways along with the most promising ongoing clinical trials, which will hopefully revolutionize the treatment landscape of this orphan disease in the foreseeable future.

show abstract

Magnetic Resonance of Small Bowel Tumors

Cited by 20 publications

References 54 publications

Evaluation of duodenal perfusion by contrast‐enhanced ultrasonography in dogs with chronic inflammatory enteropathy and intestinal lymphoma

Evaluation of duodenal perfusion by contrast‐enhanced ultrasonography in dogs with chronic inflammatory enteropathy and intestinal lymphoma

Small Bowel Neoplasms: A Pictorial Review

Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management

Contact Info

Product

Resources

About